GlassScriptPhysician profile
Emily Mitchell Clark
NPI 1598115032
$4,459.51
in general payments reported to CMS, 2019-2025
31 companies · $865 in 2025
The $865 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $854 · 2022: $935 · 2023: $608 · 2024: $1,197 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,657 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.51 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.94 | 2021-2025 | Ubrelvy, Lo Loestrin Fe, Orilissa |
| Biogen, INC. | $472.41 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $444.31 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $407.30 | 2024-2025 | |
| Myovant Sciences INC. | $268.77 | 2021-2022 | |
| Pfizer INC. | $219.30 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $183.54 | 2023-2025 | |
| Exeltis, USA INC. | $144.92 | 2021-2024 | Slynd |
| Argenx US, INC. | $142.11 | 2024 | Vyvgart Hytrulo |
| Millicent US INC | $126.02 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Astellas Pharma US INC | $121.83 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $120.87 | 2021-2022 | |
| Gynesonics, INC. | $107.15 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $104.48 | 2022-2025 | Nexplanon |
| Emd Serono, INC. | $94.05 | 2023-2024 | Mavenclad |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $79.57 | 2021-2024 | |
| Therapeuticsmd, INC. | $59.55 | 2021-2022 | |
| Hologic Sales and Service, LLC | $55.55 | 2022-2024 | Aptima, Third Wave, Thinprep 2000 Processor |
| Agile Therapeutics, INC. | $48.84 | 2021-2022 | |
| Genentech USA, INC. | $42.13 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Almatica Pharma LLC | $33.77 | 2021 | |
| Aspira Women'S Health INC | $31.19 | 2022 | |
| Coopersurgical, INC. | $30.93 | 2024-2025 | Paragard T 380a |
| Applied Medical Resources Corporation | $27.40 | 2024 | |
| Evofem Biosciences, INC. | $26.93 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.23 | 2021 | |
| Olympus America INC. | $17.10 | 2021 | |
| Avion Pharmaceuticals | $14.28 | 2021 | |
| Blueprint Medicines Corporation | $14.22 | 2021 | |
| Boston Scientific Corporation | $14.04 | 2024 | Advantage System |
| Ibsa Pharma INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mitchell Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.